Happy Friday!
July is almost over, which means that Juvenile Idiopathic Arthritis Awareness Month is drawing to a close. But it’s not too late to bring attention to this often overlooked disease, this month or any other, and we have some ideas here. In this week’s Editor’s Choice, we have tips for traveling with Atypical Hemolytic Uremic Syndrome (aHUS), a potentially life-threatening illness characterized by the formation of blood clots in small blood vessels. We also have details on some advances in the field of nanomedicine designed to make treatment more efficient. And finally, we have a story about how two patients with Familial Chylomicronemia Syndrome have helped to spur changes at the FDA. We hope you enjoy your weekend!
Traveling with Atypical Hemolytic Uremic Syndrome: Tips for Patients
This syndrome can affect multiple organ systems and especially the kidneys, so it’s worth the effort to make sure that you have everything that you need.
New Technique Makes Nanomedicine More Efficient
Although nanomedicine is uniquely poised to treat diseases through nanotechnology, it typically comes with a price: poor blood circulation.
Familial Chylomicronemia Syndrome: Two Patients Help Spur Changes at the FDA
They were shocked when they realized that the medical experts on the committee didn’t actually have much experience treating the disorder, which seemed like a major flaw in the process.
